Shares of Moderna, Inc. (MRNA) surged 5.7% in the past 24 hours during Monday's trading session, outperforming the broader market. This significant stock price movement can be attributed to the company's announcement that the U.S. government, through the Biomedical Advanced Research and Development Authority (BARDA), has awarded Moderna $590 million to accelerate the development of an mRNA-based vaccine program aimed at preventing the spread of the H5N1 virus, also known as bird flu, in humans.

Moderna intends to utilize these funds to support the late-stage development of mRNA-1018, its investigational pandemic influenza vaccine against H5 and H7 avian influenza viruses. The funding will also enable the expansion of clinical studies for up to five additional pandemic influenza subtypes. The company had already initiated a phase I/II study on mRNA-1018 in 2023 and plans to share data from this study at a future medical meeting.

The announcement of this substantial government funding has been well-received by investors, as it is expected to bolster Moderna's financial performance, which faced a setback last week after the company slashed its 2025 revenue guidance. Unlike traditional vaccines, mRNA-based vaccines like Moderna's can be developed quickly and offer manufacturing scalability, a significant advantage in case new strains or variants of the virus emerge.